Hejing Biotech announced that the SGC001 injection independently developed by its holding subsidiary Shunjing Pharmaceutical is carrying out phase IIa clinical studies on the “Expected Severe Acute Pancreatitis” indication; the study began one after another at various research centers in August 2026, and recently completed the first case of patient enrollment.

Hejing Biotech announced that the SGC001 injection independently developed by its holding subsidiary Shunjing Pharmaceutical is carrying out phase IIa clinical studies on the “Expected Severe Acute Pancreatitis” indication; the study began one after another at various research centers in August 2026, and recently completed the first case of patient enrollment.